GlassScriptPhysician profile
Brandon Wuerth
NPI 1245643006
$4,224.84
in general payments reported to CMS, 2019-2025
22 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $89.22 · 2021: $209 · 2022: $334 · 2023: $658 · 2024: $1,134 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.64 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,293.58 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,215.26 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $408.54 | 2023-2025 | Entyvio, Gattex |
| Janssen Pharmaceuticals, INC | $223.15 | 2019-2021 | |
| Perspectum Diagnostics LTD | $148.36 | 2023 | Livermultiscan |
| E.R. Squibb & Sons, L.L.C. | $130.92 | 2022 | |
| Pfizer INC. | $109.78 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $100.17 | 2023 | Stelara |
| Erbe USA INC | $100.00 | 2024 | |
| Organon LLC | $87.28 | 2023-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $81.31 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $73.51 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.50 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $36.86 | 2020-2024 | Dificid |
| Celltrion USA INC. | $36.56 | 2024-2025 | Vegzelma, Zymfentra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.68 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $20.02 | 2024 | Voquezna |
| Conmed Corporation | $18.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2023 | Cyltezo |
| Shionogi INC | $16.77 | 2019 | |
| Braintree Laboratories, INC. | $14.69 | 2024 | Suflave |
| Evoke Pharma, INC. | $13.23 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Wuerth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.